The use of omega-3 fatty acids for depression treatment is of considerable interest, in part due to the inadequate efficacy and tolerability of standard antidepressant medications. Although several metaanalyses have reported positive outcomes for omega-3 fatty acid treatment of depression, [1] [2] [3] [4] [5] the metaanalysis by Bloch and Hannestad suggests no significant benefit. 6 However, caution must be undertaken when interpreting these findings. Omega-3 fatty acids have been found to have greater effects for trials examining Diagnostic and Statistical Manual of Mental Disorders (DSM)-defined major depressive disorder (MDD) than for trials examining depressive symptoms in symptomatic individuals without a formal psychiatric diagnosis. 3 This meta-analysis, however, includes studies and subjects that were not rigorously diagnosed as having strictly DSM-defined MDD. 6 In fact, according to their third inclusion criterion, trials examining the efficacy of omega-3 fatty acids in subjects who may not have received a formal diagnosis were also included. It is therefore not accurate to describe this paper as a meta-analysis of MDD studies (for example, from the first line of Abstract to the last paragraph of Discussion). 6 The major concern is the inclusion of Rogers and colleagues' clinical trial, 7 which represented a 31.7% weight of the pooled estimate among a total of 13 selected clinical trials. In their study, individuals were enrolled for omega-3 fatty acid supplementation according to a self-rating of the short form of the Depression, Anxiety and Stress Scales in settings such as general practice surgeries, shopping malls and university freshman fairs, 7 indicating that individuals were not rigorously evaluated for MDD by health professionals. When psychiatrists use the term 'depression,' it almost invariably means a depressive disorder defined by the presence of characteristic clinical psychopathology and/or by meeting the DSM or International Classification of Diseases (ICD) diagnostic criteria. Although the use of self-rating scales is convenient to screen for depressive disorders, a high score obtained on a self-rating scale did not necessarily indicate the presence of depressive psychopathology. In addition, in Rogers and colleagues' study, 7 they assessed the baseline depression severity by using self-rated scales of Depression, Anxiety and Stress Scales, rather than clinician-rated measurement determined primarily by the Hamilton Depression Rating Scale or the Montgomery Asberg Ratings Scales in other included trials. Furthermore, the baseline Beck Depression Inventory score fell below the cutoff value, which means that the majority of subjects in Rogers's study 7 may not suffer from meaningful levels of depressive symptoms. We agree that the severity of depression at baseline is a Figure 1 Forest plot of treatment effects of omega-3 fatty acids for major depression.
Letters to the Editor significant moderator of the antidepressant effect of omega-3 fatty acid supplementation as identified by Bloch and Hannestad. However, in order to more reliably detect antidepressant effects of omega-3 fatty acids, rather than examine a heterogeneous group of individuals with depressive symptoms of varying severity, we believe that it is more appropriate to focus on a specific population of patients with MDD who have been recruited using standard diagnostic procedures. Therefore, for all the above reasons, the Rogers' study 7 should have been excluded from Bloch and Hannestad's meta-analysis.
After excluding Rogers and colleagues' study, we performed a modified meta-analysis by using RevMan program (Review Manager, version 5.1, Copenhagen: Nordic Cochrane Centre, Cochrane Collaboration, 2011). With 267 patients with omega-3 treatment and 238 patients with placebo treatment from 12 trials included, a significant antidepressant effect of omega-3 fatty acids could be found (standard mean difference (SMD) = 0.23, 95% confidence interval: 0.05, 0.42, P = 0.01, by fixed effects model) (Figure 1 ). There was significant heterogeneity among studies (w 2 = 41.2, df = 11, P < 0.0001, I 2 = 73%). The pooled effect remained significant even when using random effects model (SMD = 0.42, 95% confidence interval: 0.04, 0.79, P = 0.03). We found that the effect of the study by Lucas et al. 8 (SMD = À0.67) is apparently discrepant from other studies (Figure 1) . The discrepancy may be explained by the exclusion of subjects with severe depression from their study. However, Egger's regression analysis showed a statistically significant result (t = 3.53, df = 10, P = 0.005), suggesting publication bias toward studies with larger effect but smaller sample size.
Considering that only predominant eicosapentaenoic acid (EPA) supplements appeared to be the effective component, 3, 4 we performed a subgroup analysis based on the omega-3 fatty acid composition as an effect modifier. Consistent with Martins et al. 3 and Sublette et al., 4 patients treated with supplements containing X60% EPA showed a significant effect, but not those with supplements containing EPA < 60% (Figure 2 ). Significant heterogeneity was found among studies in the higher-EPA group, but not in the lower-EPA group. We did not find publication bias in either group. The distinction between studies with different EPA composition may account for the heterogeneity in our overall meta-analysis.
Our meta-analysis showed a significant antidepressant effect of EPA in patients with DSM-defined MDD. However, omega-3 fatty acids may not have 'moodimproving' effects in individuals with only nonclinical depressive symptoms. In addition, our analysis confirmed the discrepancy in antidepressant effects between supplements with different EPA contents. 3, 4, 9 Larger and well-designed trials with EPA-rich supplement, as monotherapy or as adjunctive treatment to pharmaceutical antidepressants, should be performed. Meta-analyses, just like randomized clinical trials, may be affected by potential bias arising from the selection criteria. In order to avoid unacceptable heterogeneity, both types of investigation should specifically define the diagnostic status of included subjects. 
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